NCT06682637撤回2 期
Melflufen for Elderly Myeloma Patients in Second or Subsequent Relapse
Fondazione EMN Italy Onlus10 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2025年3月26日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 发起方
- 入组人数
- 30
- 试验地点
- 10
- 主要终点
- Overall Response Rate
研究概览
简要总结
This is a pilot study aimed to evaluate the efficacy and tolerability of melflufen plus dexamethasone in elderly patients at second relapse.
Thirty elderly patients at second or subsequent relapse.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 70 Years 至 80 Years（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients affected by MM progressed or relapsed after 2 or more previous lines of therapy.
- •Patient is, in the investigator's opinion, willing and able to comply with the study visits and procedures required per protocol.
- •Patient has provided written informed consent in accordance with federal, local, and institutional guidelines prior to initiation of any study-specific activities or procedures. Subject does not have kind of condition that, in the opinion of the Investigator, may compromise the ability of the subject to give written informed consent and patient is, in the investigator(s) opinion, willing and able to comply with the protocol requirements.
- •Life expectancy ≥ 3 months
- •Previous exposure to, at least, one drug of all the following categories: an anti-CD38 MoAbs, an IMiD, and a proteasome inhibitor.
- •Age ≥ 70 and ≤ 85 years.
- •ECOG performance status ≤
- •Subject must have serum monoclonal paraprotein (M-protein) level ≥0.5 g/dL or urine M-protein level ≥200 mg/24 hours, or serum immunoglobulin involved free light chain ≥10 mg/dL and abnormal serum immunoglobulin kappa lambda free light chain ratio.
- •LVEF ≥40% as determined by a MUGA scan or ECHO.
- •Adequate hepatic function characterized by the following:
- •oTotal bilirubin ≤1.5 x ULN. oAST ≤2.5 x ULN oALT ≤2.5 x ULN.
- •Estimated creatinine clearance ≥30 mL/min (according to the Cockcroft Gault formula, by 24-hour urine collection for creatinine clearance, or per the local institutional standard method).
- •Adequate BM function characterized by the following:
- •Absolute neutrophil count ≥1.0 × 109/L (use of granulocyte-colony stimulating factors is permitted if completed at least 7 days prior to planned start of dosing).
- •Platelet count ≥50 × 109/L (transfusion support is not permitted).
- •Hemoglobin ≥8 g/dL (transfusion support is permitted).
- •Non-vasectomized male patients agree to practice appropriate methods of birth control
排除标准
- •Previous exposure to chemotherapy (i.e. melphalan, high-dose melphalan and/or cyclophosphamide) with the exception of patients who have received an autologous stem cell transplantion with a progression free survival of at least 36 month.
- •Plasma cell leukemia.
- •Systemic amyloid light chain amyloidosis.
- •POEMS Syndrome.
- •Central Nervous System (CNS) disease localization.
- •Subject with another tumor, not including MM, that required ongoing treatment or therapy completed less than 6 months before eligibility confirmation, and considered at substantial risk of relapse in the following 12 months.
- •Active HBV, HCV, SARS-CoV2, HIV, or any active, uncontrolled bacterial, fungal, or viral infection. Active infections must be resolved at least 14 days prior to eligibility confirmation.
- •Subject has any concurrent medical condition or disease (e.g. active systemic infection) that is likely to interfere with study procedures or results, or that in the opinion of the investigator would constitute a hazard for participating in this study.
- •Subject has clinically significant cardiac disease, including:
- •Myocardial infarction within 6 months before trial eligibility
- •Uncontrolled disease/condition related to or affecting cardiac function (e.g. unstable angina, congestive heart failure, New York Heart Association Class III-IV)
- •Clinically significant ECG abnormalities.
研究组 & 干预措施
Melflufen and Dexamethasone
Experimental
- Melflufen 40 mg total dose (30 mg in patients with body weight ≤60 kg and/or in patients with eGFR<45 mL/min) intravenously on day 1.
- Dexamethasone 10 mg orally or intravenously on day 1-2, 8-9, 15-16, 22-23.
干预措施: Melflufen (Drug)
Melflufen and Dexamethasone
Experimental
- Melflufen 40 mg total dose (30 mg in patients with body weight ≤60 kg and/or in patients with eGFR<45 mL/min) intravenously on day 1.
- Dexamethasone 10 mg orally or intravenously on day 1-2, 8-9, 15-16, 22-23.
干预措施: Dexamethasone (Drug)
结局指标
主要结局
Overall Response Rate
时间窗: approximately 6 months after the enrolled of the last participant and an updated analysis will be conducted at approximately 8 to 12 months.
rate of participants who achieve a PR or better (PR+VGPR+CR+sCR) according to IMWG response criteria during the treatment.
次要结局
- DURATION OF RESPONSE(after 2.5 years)
- PROGRESSION-FREE SURVIVAL(after 6 months)
- TIME TO PROGRESSION(after 2.5 years)
- PROGRESSION-FREE SURVIVAL 2(after 2.5 years)
- OVERALL SURVIVAL(after 2.5 years)
- TIME TO RESPONSE(after 2.5 years)
研究者
研究点 (10)
Loading locations...
相似试验
已完成
2 期
A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaMultiple MyelomaNCT02963493Oncopeptides AB157
已完成
2 期
Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple MyelomaMultiple MyelomaNCT00116961University of Michigan Rogel Cancer Center40
已完成
1 期
Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell TransplantationMultiple MyelomaNCT01690143University of Alabama at Birmingham45
已完成
1 期
Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple MyelomaMultiple MyelomaNCT02148913Corewell Health West18
已完成
3 期
Combination of Lenalidomide and Dexamethasone in Treatment of Multiple MyelomaMultiple MyelomaNCT01090089Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH348